INTRODUCTION: With expanding indications for programmed death 1 (PD-1) axis inhibitors in non-small cell lung cancer (NSCLC), acquired resistance (AR) to these therapies is increasingly being encountered. We sought to characterize clinical patterns of AR to PD-1 axis inhibitors in patients with advanced NSCLC, and evaluate subsequent outcome and management strategies for such patients. METHODS: Patients with NSCLC who developed AR to PD-1 axis inhibitor therapy initiated between December 2009 and February 2016 at one institution were identified and examined by clinical and radiographic features. AR was defined as progressive disease after initial response by either Response Evaluation Criteria in Solid Tumors v1.1 or immune-related response criteria. RESULTS: Twenty-six patients with AR to PD-1 axis inhibitor therapy were identified and evaluated. Median time to AR was 313 days; the 2-year survival rate from AR was 70% (95% confidence interval: 0.53-0.92). Twenty patients (77%) experienced AR in lymph nodes (LNs), including 11 patients with LN-only progression. Twenty-three (88%) patients had recurrence limited to one (54%) or two (35%) sites of disease. Fourteen patients (54%) continued PD-1 axis inhibitor therapy beyond progression. Three patients were re-challenged with the same PD-1 axis inhibitor after holiday from and progression off therapy, 2 again responded. Fifteen patients (58%) received local therapy to site(s) of AR, 11 continued respective PD-1 axis inhibitor after local therapy. The 2-year survival rate from AR among these 15 patients was 92% (95% confidence interval: 0.77-1). CONCLUSIONS: Acquired resistance to PD-1 axis inhibitors is often limited to one or two sites when local therapy and continuation of PD-1 axis inhibitor therapy can result in prolonged benefit. LN metastases appear to be particularly susceptible sites to AR. When progression of disease following response occurs after holiday from PD-1 axis inhibitor, re-challenge can again lead to tumor regression.
INTRODUCTION: With expanding indications for programmed death 1 (PD-1) axis inhibitors in non-small cell lung cancer (NSCLC), acquired resistance (AR) to these therapies is increasingly being encountered. We sought to characterize clinical patterns of AR to PD-1 axis inhibitors in patients with advanced NSCLC, and evaluate subsequent outcome and management strategies for such patients. METHODS:Patients with NSCLC who developed AR to PD-1 axis inhibitor therapy initiated between December 2009 and February 2016 at one institution were identified and examined by clinical and radiographic features. AR was defined as progressive disease after initial response by either Response Evaluation Criteria in Solid Tumors v1.1 or immune-related response criteria. RESULTS: Twenty-six patients with AR to PD-1 axis inhibitor therapy were identified and evaluated. Median time to AR was 313 days; the 2-year survival rate from AR was 70% (95% confidence interval: 0.53-0.92). Twenty patients (77%) experienced AR in lymph nodes (LNs), including 11 patients with LN-only progression. Twenty-three (88%) patients had recurrence limited to one (54%) or two (35%) sites of disease. Fourteen patients (54%) continued PD-1 axis inhibitor therapy beyond progression. Three patients were re-challenged with the same PD-1 axis inhibitor after holiday from and progression off therapy, 2 again responded. Fifteen patients (58%) received local therapy to site(s) of AR, 11 continued respective PD-1 axis inhibitor after local therapy. The 2-year survival rate from AR among these 15 patients was 92% (95% confidence interval: 0.77-1). CONCLUSIONS: Acquired resistance to PD-1 axis inhibitors is often limited to one or two sites when local therapy and continuation of PD-1 axis inhibitor therapy can result in prolonged benefit. LN metastases appear to be particularly susceptible sites to AR. When progression of disease following response occurs after holiday from PD-1 axis inhibitor, re-challenge can again lead to tumor regression.
Authors: D Isla; J de Castro; R García-Campelo; P Lianes; E Felip; P Garrido; L Paz-Ares; J M Trigo Journal: Clin Transl Oncol Date: 2019-07-31 Impact factor: 3.405
Authors: Jonathan D Schoenfeld; Anita Giobbie-Hurder; Srinika Ranasinghe; Katrina Z Kao; Ana Lako; Junko Tsuji; Yang Liu; Ryan C Brennick; Ryan D Gentzler; Carrie Lee; Joleen Hubbard; Susanne M Arnold; James L Abbruzzese; Salma K Jabbour; Nataliya V Uboha; Kevin L Stephans; Jennifer M Johnson; Haeseong Park; Liza C Villaruz; Elad Sharon; Howard Streicher; Mansoor M Ahmed; Hayley Lyon; Carrie Cibuskis; Niall Lennon; Aashna Jhaveri; Lin Yang; Jennifer Altreuter; Lauren Gunasti; Jason L Weirather; Raymond H Mak; Mark M Awad; Scott J Rodig; Helen X Chen; Catherine J Wu; Arta M Monjazeb; F Stephen Hodi Journal: Lancet Oncol Date: 2022-01-13 Impact factor: 41.316
Authors: Matthew D Hellmann; Barzin Y Nabet; Hira Rizvi; Aadel A Chaudhuri; Daniel K Wells; Mark P S Dunphy; Jacob J Chabon; Chih Long Liu; Angela B Hui; Kathryn C Arbour; Jia Luo; Isabel R Preeshagul; Everett J Moding; Diego Almanza; Rene F Bonilla; Jennifer L Sauter; Hyejin Choi; Megan Tenet; Mohsen Abu-Akeel; Andrew J Plodkowski; Rocio Perez Johnston; Christopher H Yoo; Ryan B Ko; Henning Stehr; Linda Gojenola; Heather A Wakelee; Sukhmani K Padda; Joel W Neal; Jamie E Chaft; Mark G Kris; Charles M Rudin; Taha Merghoub; Bob T Li; Ash A Alizadeh; Maximilian Diehn Journal: Clin Cancer Res Date: 2020-02-11 Impact factor: 12.531
Authors: Giulio Metro; Alfredo Addeo; Diego Signorelli; Alessio Gili; Panagiota Economopoulou; Fausto Roila; Giuseppe Banna; Alessandro De Toma; Juliana Rey Cobo; Andrea Camerini; Athina Christopoulou; Giuseppe Lo Russo; Marco Banini; Domenico Galetta; Beatriz Jimenez; Ana Collazo-Lorduy; Antonio Calles; Panagiotis Baxevanos; Helena Linardou; Paris Kosmidis; Marina C Garassino; Giannis Mountzios Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: Kanishka Rangamuwa; Tracy Leong; Clare Weeden; Marie-Liesse Asselin-Labat; Steven Bozinovski; Michael Christie; Tom John; Phillip Antippa; Louis Irving; Daniel Steinfort Journal: Transl Lung Cancer Res Date: 2021-06
Authors: Kanishka Rangamuwa; Tracy Leong; Steven Bozinovski; Michael Christie; Thomas John; Phillip Antippa; Louis Irving; Daniel Steinfort Journal: Transl Lung Cancer Res Date: 2021-06